AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing

Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas